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Risk factorBackground: Antituberculosis drugs cause hepatotoxicity in some individuals leading to
acute liver failure, which results in death. Such phenomena limit the clinical use of drugs,
contributing to treatment failure that possibly causes drug resistance. Furthermore, asso-
ciated risk factors for the development of antituberculosis-drug-induced hepatotoxicity
(anti-TB-DIH) are found to be controversial among different study findings.
Methods: A prospective cohort study was conducted from May 2014 to October 2014 in
Dawro Zone, Tercha District Hospital Laboratory, South Ethiopia. One hundred and
twenty-four new tuberculosis-positive individuals available from Tercha Hospital and five
health centers during data collection were consecutively included. The sociodemographic
data and anthropometric measurement were obtained. Then, 5 mL of venous blood was
drawn from each individual, and the alanine transaminase, aspartate transaminase, and
total bilirubin were measured photometrically at baseline, and then continuously moni-
tored by measuring these liver enzymes every 2 weeks for 2 months. Data were analyzed
with SPSS version 20 for Windows (SPSS Inc., Chicago, IL, USA).
Results: The incidence of anti-TB-DIH was found to be 8% (10 patients out of 124). Raised
serum transaminase and bilirubin level, as well as signs and symptoms of hepatotoxicity
(nausea, anorexia, vomiting, malaise, and jaundice), were observed in the cases. The onset
of hepatotoxicity ranged from 13 days to 58 days (median, 26 days) after treatment was
initiated. Of the various risk factors analyzed, only high alcohol intake was associated with
the incidence of anti-TB-DIH (odds ratio = 9.3, 95% confidence interval 1.8–47, p < .007). Age,
gender, extent of tuberculosis disease, and malnutrition were not significantly associated
with anti-TB-DIH.
Conclusion: The incidence of anti-TB-DIH in Dawro Zone was high. The drug responsible for
the hepatotoxicity was not known. However, chronic high alcohol intake was associated
with the development of anti-TB-DIH.
 2015 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.
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Tuberculosis (TB) continues to remain a significant infectious
disease across much of the world. It poses a formidable
socioeconomic burden on the individual and on the society.
There were 8.6 million newer TB cases and an estimated
1.3 million deaths that occurred worldwide in 2012 [1]. New
cases of TB-infected individuals are treated by a combina-
tion of four drugs: isoniazid (INH), rifampin (RIF), pyrazi-
namide (PZA), and ethambutol [2]. However, a variety of
adverse reactions of these drugs have been reported; one
of the well-known toxic effects is hepatotoxicity [3].
Antituberculosis-drug-induced hepatotoxicity (anti-TB-DIH)
may result from the direct toxicity of the primary com-
pound, a metabolite, or from an immunologically mediated
response, affecting hepatocytes, biliary epithelial cells, and/
or liver vasculature [4,5]. Most types of anti-TB-DIH is due
to metabolic idiosyncrasy due to the metabolites released
or accumulated during the metabolic process. These hyper-
sensitivity or metabolic reactions occur largely independent
of the dose [6].
Anti-TB-DIH is confirmed by an elevated level of aspartate
transaminase (AST) or alanine transaminase (ALT) to five
times the upper limit of normal (ULN), in the absence of jaun-
dice or other symptoms, or up to three times the ULN in the
presence of symptoms of hyperbilirubinemia (bilirubin 2
times the ULN) [7]. Although a vast majority of patients toler-
ate the drugs, some 3–25% develops anti-TB-DIH worldwide.
Anti-TB-DIH accounts for 7% of reported drug adverse effects,
2% of jaundice in hospitals, and approximately 30% of fulmi-
nant liver failure [8,9]. The spectrum of anti-TB-DIH is diverse,
ranging from asymptomatic rise in transaminase (to fivefold)
in 2.3–28% to acute liver failure in approximately <0.01% of
the individuals [10].
There are factors that contribute to the development of
anti-TB-DIH [2,3,7]. Some studies reported that the history of
chronic alcohol intake is a predisposing factor for anti-TB-
DIH [11,12]. Several studies reported that old age is a potential
risk factor for anti-TB-DIH [3,7,13]. However, a study in Nepal
revealed that the incidence of anti-TB-DIH was higher in
younger patients [3]. Some studies suggested that female gen-
der is an independent predictor of anti-TB-DIH [3,14]. How-
ever, a recent report suggested that males have a higher risk
of developing anti-TB-DIH [15]. A study reported that there
was no significant association between the extent of TB dis-
ease and the incidence of anti-TB-DIH [16]. However, extrapul-
monary organ involvement was reported to be associatedwith
the incidence of anti-TB-DIH in studies from India [17,18].
Some studies from Nepal [3], Spain [28], and India [11,18]
showed that malnourishment had a significant association
with the incidence of anti-TB-DIH.
The risk factors that contribute to the development of
anti-TB-DIH are still obscure and controversial. Understand-
ing anti-TB-DIH is restricted by the difference in study
population, definition of hepatotoxicity, and monitoring prac-
tices. There was no study that determined the incidence of
anti-TB-DIH and assessed the risk factors of anti-TB-DIH
among TB patients in Dawro Zone. Therefore, this studywas aimed to determine the incidence of anti-TB-DIH and
identify the possible risk factors of anti-TB-DIH among TB
patients in Dawro Zone, South Ethiopia.
Materials and methods
Study setting and study participants
A prospective cohort study was conducted from May 2014 to
October 2014 in Southern Ethiopia. One hundred and twenty-
fournewlyTB-infected individualswithnegativehepatitisBsur-
face antigen, anti-hepatitis C virus (HCV) antibodies, and
human-immunodeficiency-virus test, and having complete
recorded data were included in this study consecutively.
Patients who had ALT and AST values greater than two times
theULN (i.e.,ULN > 42U/Land37U/L, respectively), andpatients
positive for hepatitis B surface antigen, anti-HCVantibodies, as
well as retreatment case of TB were excluded from the study.
Data collection and laboratory testing
The sociodemographic and clinical datawere collected using a
structured questionnaire and checklist. Then, 5-mL venous
blood samples were collected using test tubes that contain
separator gels and allowed to clot for 30 min. After retracting
the clot, the samples were centrifuged at 3000 g for 10 min.
Pure serum samples were transferred to Nunc tubes, and
screened for hepatitis B and C virus using rapid hepatitis B sur-
face antigen and rapid anti-HCV test kits, respectively. The
baseline measurements of ALT, AST, and total bilirubin were
performed photometrically using Mindray BS-200E Chemistry
Analyzermachine (ShenzhenMindray Bio-Medical Electronics
Co., Ltd.) before the initiation of anti-TB treatment. After the
initiation of anti-TB treatment, the patients were examined
both physically and biochemically every week for 2 months.
The standard operating procedures andmanufacturer instruc-
tionswere strictly followed throughout the procedures, and all
reagents were prepared according to the manufacturer’s
instruction. A quality-control run was undertaken for all labo-
ratory tests in this study.
Statistical analysis
Data were coded, entered, and cleaned using statistical soft-
ware (EpiData, version 3.1), and then exported to and ana-
lyzed with SPSS, version 20 for Windows (SPSS Inc., Chicago,
IL, USA). The mean standard deviation (SD) and frequency
of variables were calculated. The bivariate and multivariate
logistic regression was calculated to evaluate the possible
association of the variables, and p < .05 was considered as sta-
tistically significant.
Ethical consideration
The ethical clearance was obtained from the Jimma Univer-
sity Ethical Review Committee, and an official letter was writ-
ten to Dawro Zone Health Bureau. For voluntary participation,
the research participants signed an informed consent based
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even discomfort caused by data/sample collection proce-
dures, as well as any benefits. Moreover, issues concerning
intervention especially in the case of induced hepatotoxicity
were discussed with concerned bodies to continue or discon-
tinue treatment.
Results
Demographic and anthropometric data
One hundred and twenty-four TB patients taking anti-TB
drugs were involved in this study and were followed for
2 months. Among them, 66 (53.2%) were females. The ages
of the cases ranged from 10 years to 80 years with the mean
(±SD) age being 34.5 (±15.2 years), but the highest number of
participants was found in the age group of 20–49 years, which
is 84 (67.7%). The body-mass-index (BMI) measurement of the
participants ranged from 17.08 kg/m2 to 24.78 kg/m2, the
mean value being 20.60 kg + 1.77 kg. The BMI measurement
of the majority (119 [96%]) of the participants was within
the normal range (i.e., 18.5–24.00 kg/m2 [Table 1]).
Clinical and laboratory data, and hepatotoxicity of study
patients
Out of 124 participants, 13 of them were taking different
antibiotics during the study period, of which nine (69%) wereTable 2 – Laboratory Data (mean ± standard deviation) of patien
centers, Southern Ethiopia, from May 2014 to October 2014.
Laboratory test
ALT (U/L) Baseline
During treatment (peak value)
AST (U/L) Baseline
During treatment (peak value)
Total bilirubin (mg/dL) Baseline
During treatment (peak value)
Note: ALT = alanine transaminase; anti-TB-DIH = antituberculosis-drug-in
Table 1 – Demographic and anthropometric data of study partici
Southern Ethiopia, from May 2014 to October 2014.
Characteristics
Gender Male
Female
Total
Age (y) 10–19
20–49
>50
Total
BMI (kg/m2) Underw
Norma
Overw
Total
Note: BMI = body mass index; y = year.males and four (31%) were females. None of them were
reported to be taking paracetamol or other potentially hepato-
toxic drugs during the study or 1 month prior to the study per-
iod. Among the 124 participants, eight (6.5%) were reported to
be alcoholics, of whom six (75%) were females and two (25%)
were males. Smear-positive pulmonary TB accounted for 99
(79.8%) of all cases, and extrapulmonary TB accounted for
about 25 (20.2%) cases.
During the 5-month study period, 10 patients out of 124
developed anti-TB drug hepatotoxicity, which was confirmed
by clinical examination and liver function test. They showed
elevated serum concentrations of ALT, AST, and total bilirubin
beyond five times the ULN with or without symptoms.
Patients with anti-TB-DIH had their ALT, AST, and bilirubin
total values (mean ± SD) were 22.70 ± 9.71 U/L, 21.60 ± 6.67
U/L, and 0.34 ± 0.21 mg/dL, respectively, at baseline measure-
ment, and their peak values during treatment were 304.80
± 93.67 U/L, 261.80 ± 66.07 U/L, and 1.86 ± 0.91 mg/dL, respec-
tively (Table 2).
Among the total 10 anti-TB-DIH cases, female patients
account for the highest number [6 (60%)]. Most of the patients
who had developed ant-TB-DIH showed the same signs and
symptoms (malaise, anorexia, vomiting, nausea, and jaun-
dice). The most common symptoms being nausea and anor-
exia (90% and 80%, respectively), followed by malaise and
jaundice being 60% and 40%, respectively (Table 4). The time
interval from the initiation of treatment to the onset of hepato-
toxicitywas 13–58 days (medianof 26 days) (seeTables 3 and6).ts at Dawro Zone among Tercha Hospital and five health
Patients with anti-TB-DIH
(n = 10)
Patients without anti-TB-DIH
(n = 114)
22.70 ± 9.71 23.34 ± 3.67
304.80 ± 93.67 33.90 ± 5.21
21.60 ± 6.67 27.74 ± 4.54
261.80 ± 66.07 30.13 ± 2.22
0.34 ± 0.21 0.45 ± 0.33
1.86 ± 0.91 0.65 ± 0.77
duced hepatotoxicity; AST = aspartate transaminase.
pants at Dawro Zone Tercha Hospital and five health centers,
No. (%)
58 (46.8)
66 (53.2)
124 (100)
20 (16.1)
84 (67.8)
20 (16.1)
124 (100)
eight 4 (3.2)
l 119 (96)
eight 1 (0.8)
124 (100)
Table 3 – Laboratory data (mean + standard deviation) based on gender of patients at Dawro Zone among Tercha Hospital and
five health centers, Southern Ethiopia, from May 2014 to October 2014.
Parameters Cutoff value Patients with DIH (n = 10), No. (%)
AST (U/L) >3  ULN + symptoms Male 111 3 (30)
Female 93 1 (10)
>5  ULN with/without symptom Male 185 4 (40)
Female 155 2 (20)
ALT (U/L) >3  ULN + symptoms Male 126 1 (10)
Female 96 3 (30)
>5  ULN with/without symptom Male 210 3 (30)
Female 160 3 (30)
Total bilirubin (mg/dL) >2  ULN Male 2.4 2 (20)
Female 2.4 3 (30)
Note: ALT = alanine transaminase; AST = aspartate transaminase; DIH = drug-induced hepatotoxicity; ULN = upper limit of normal.
Table 4 – Clinical presentations of antituberculosis-drug-induced hepato-
toxicity in patients at Dawro Zone Tercha Hospital and five health centers,
Southern Ethiopia, from May 2014 to October 2014.
Signs & symptoms Patients with anti-TB-DIH, No. (%)
Vomiting 4 (40)
Jaundice 4 (40)
Anorexia 8 (80)
Nausea 9 (90)
Malaise 6 (60)
Note: Anti-TB-DIH = antituberculosis-drug-induced hepatotoxicity.
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 5 ( 2 0 1 6 ) 1 4 –2 0 17Those who had developed anti-TB-DIH were followed
weekly for 3 weeks with liver function test (AST, ALT, and total
bilirubin) until their liver-enzyme levels returned to normal or
the baseline state. Liver toxicity resolved within 21 days
(median of 20 days; Table 5), and continued treatment.
Factors associated with hepatotoxicity
Alcoholism (which is defined as consuming >35 units and >28
units of alcohol per week for at least 10 years for men and
women, respectively) was found to be significantly associated
with the incidence of anti-TB-DIH (crude odds ratio = 9.343,
95% confidence interval 1.8–47.3). According to this study, BMI
(kg/m2), extentofTBdisease, gender, andagehadnosignificant
association with the incidence of anti-TB-DIH (Table 7).
Discussion
One hundred and twenty-four cohorts of newly diagnosed TB
patients who were negative for human immunodeficiencyTable 5 – Follow-Up result of patients who had antituberculosis
n = 10) at Dawro Zone Tercha Hospital and five health centers, S
Test 1st week
ALT (U/L) 324 ± 60.10
AST (U/L) 268 ± 48.42
Total bilirubin (mg/dL) 1.92 ± 0.710
Note: ALT = alanine transaminase; AST = aspartate transaminase.virus and hepatitis B and C, and started taking anti-TB drugs
were included in this study. The analysis in this study showed
the incidence of anti-TB-DIH to be 8.1%. This incidence is
almost similar to previous reports of a study in St. Peter’s
TB Specialized Hospital, Addis Ababa, Ethiopia (8.9%) [19]
and to reports from Asia (8.0–19.8%) [3,13]. However, this inci-
dence is lower than that from Egypt (15% [2]) and higher than
that of the Western world (4.3% [19]). The variation in the
incidence of anti-TB-DIH worldwide may be attributed to
the differences in patients’ characteristics, indiscriminate
use of drugs, and the definition criteria of hepatotoxicity [20].
According to this study, the time interval for the
onset of hepatotoxicity after the initiation of treatment was
13–58 days (median, 26 days). This is similar to the result
reported in Nepal (12–60 days [median, 28 days]) [3]. One study
also reported that the onset of anti-TB-DIH to be 15–60 days
(median, 30 days) [2], which is similar to the result of this
study. But, another study [21] reported that the onset of
anti-TB-DIH in almost two-thirds of their patients (61.2%)
was within 14 days from the start of therapy.-drug-induced hepatotoxicity (mean ± standard deviation,
outhern Ethiopia, from May 2014 to October 2014.
2nd week 3rd week
135.35 ± 24.12 47.34 ± 8.21
107.08 ± 14.76 36.33 ± 7.98
1.25 ± 0.53 0.95 ± 0.34
Table 6 – Baseline characteristics of patients with antituberculosis-drug-induced hepatotoxicity and without antitubercu-
losis-drug-induced hepatotoxicity (mean ± standard deviation) at Dawro Zone Tercha Hospital and five health centers,
Southern Ethiopia, from May 2014 to October 2014.
Characteristics No. of patients (%) Patients with DIH,
No. (%)
Patients without DIH,
No. (%)
COR (95%) CI
Gender Male (ref) 58 (46.8) 4 (3.2) 54 (43.5) 1.3 (.36–5.04)
Female 66 (53.2) 6 (4.8) 60 (48.3) .74 (.12–2.34)
Extent of disease Pulmonary (ref) 99 (79.8) 7 (5.6) 92 (74.2) 1.79 (.42–7.49)
Extrapulmonary 25 (20.2) 3 (2.4) 22 (17.7) .76 (.11–1.54)
Alcohol status Alcoholic 8 (6.5) 3 (2.4) 5 (4) 9.343 (1.84–47.3)
Nonalcoholic (ref) 116 (93.5) 7 (5.6) 109 (87.9) .064 (.13–7.5)
Age (y) 10–19 20 (16.1) 2 (1.6) 18 (14.5) .11 (.4–3.76)
20–49 (ref) 84 (67.8) 7 (5.6) 67 (54) .818 (.157–4.27)
>50 20 (16.1) 1 (0.8) 19 (15.3) .474 (.039–5.688)
BMI <18.5 4 (3.2) 3 (2.4) 1 (0.8) 0
18.5–24.99 (ref) 119 (96) 7 (5.6) 112 (90.3) 0
>25 1 (0.8) 0 (0) 1 (0.8) 0
Note: BMI = body mass index; CI = confidence interval; COR = crude odds ratio; DIH = drug-induced hepatotoxicity; ref = reference group;
y = year.
Table 7 – Association of predictors with incidence of antituberculosis-drug-induced hepatotoxicity in patients taking
antituberculosis drugs in Dawro Zone Tercha Hospital and five health centers, Southern Ethiopia, from May 2014 to October
2014.
Variables COR 95% CI p
Gender Male 1.3 .36–5.04 .65
Female .74 .12–2.34 .56
Age (y) 10–19 .11 .4–3.76 .838
20–49 .818 .15–4.27 .81
>50 .474 .039–5.7 .556
BMI (kg/m2) <18.5 161,547,162 0 .999
18.5–25 11,643,038 0 .99
>25 1,454,367 0 .999
Extent of disease Pulmonary 1.792 .42–7.4 .424
Extrapulmonary .76 .11–1.54 .89
Alcohol status Alcoholic 9.3 1.8–47.3 .007
Nonalcoholic .064 .13–7.5 .92
Note: BMI = body mass index; CI = confidence interval; COR = crude odds ratio; y = year.
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was a potential risk factor for anti-TB-DIH (p < .007, odds
ratio = 9.3). Similarly, one study [12] reported that the history
of chronic alcohol intake was common among the cases.
Other studies also reported high alcohol intake as a predis-
posing factor for anti-TB-DIH [11,22]. On the contrary, a study
report from Dossing, Wilcke, Askgaard, and Nybo [23] and a
study done in Egypt [2] showed that high alcohol intake had
no correlation with the incidence of anti-TB-DIH. This differ-
ence can be explained by the fact that high alcohol intake as a
predisposing factor for anti-TB-DIH has been considered as
the most equivocal. However, according to some study
reports, higher alcohol consumption as a risk factor was
ascribed to malnutrition and glutathione store depletion [24].
Several studies reported that old age is a potential risk fac-
tor for anti-TB-DIH [3,7,13]. A study done in Egypt [21]
reported that the older age group was affected more than
the younger age group. By contrast, a study done in Nepal
[3] reported that the incidence of anti-TB-DIH was higher in
younger patients. The current study showed that there wasno correlation between age and anti-TB-DIH. In agreement
to this, another study reported that age had no significant
relation to anti-TB-DIH [25]. The discordance between our
findings and the studies done in Nepal and Egypt may be
explained by the fact that the age categorization for young
and old people is different.
Several studies suggested that female gender is an inde-
pendent predictor of anti-TB-DIH [3,14]. However, a recent
report suggested that males have a higher risk of developing
anti-TB-DIH [15]. The reason for female susceptibility was
believed to be variations in pharmacokinetics and slower
acetylation status [26]. However, gender showed no correla-
tion with anti-TB-DIH in the current study. This difference
may be explained by the fact that females are slow acetyla-
tors, and INH is cleared by acetylation. Thus, the females in
our study might have developed anti-TB-DIH by an anti-TB
drug other than INH. Some other studies are in agreement
with this current-study finding [2,27].
The extent of TB disease or the involvement of extrapul-
monary organ had no significant association with the
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congruence to this, another study reported that there was no
significant association between the extent of TB disease and
the incidence of anti-TB-DIH [16]. However, extrapulmonary
organ involvement was reported to be associated with the inci-
dence of anti-TB-DIH in studies from India [17,18]. This differ-
encemay be attributed to the fact that extrapulmonary TBmay
not necessarily indicate severity of the disease.
In this study, malnutrition, as assessed by BMI < 18.5 kg/
m2, had no significant association with anti-TB-DIH. Despite,
some studies from Nepal [3], Spain [28], and India [11,18]
showed that malnourishment had a significant association
with the incidence of anti-TB-DIH. This might be due to the
depletion of glutathione stores, which makes patients more
vulnerable to oxidative injuries. The reason for the deviation
of our finding may be explained by the fact that the majority
of patients included in our study were not malnourished.
In this study, since there was no severe hepatotoxicity, no
death was recorded. During the study period, 100% of patients
who developed anti-TB-DIH had their transaminase level
below tenfold of the ULN. Patients having signs and symp-
toms suggestive of hepatotoxicity were put under close
follow-up, and had their liver function tests monitored and
physical examination done regularly. For confirmed hepato-
toxic cases, anti-TB drugs were discontinued for some time
until it was normalized. Fortunately, all of the cases recovered
after a few days and continued treatment.
Although as a result of meta-analysis, the incidence rate of
hepatotoxicity was shown to be high with INH followed by
PZA and RIF [19]. TB patients who were included in the cur-
rent study were taking a combination of four anti-TB drugs:
INH, RIF, PZA, and ethambutol. Therefore, it was difficult to
infer which drug was responsible for the cause of hepatotox-
icity. The role of N-acetyltransferase 2 gene/enzyme polymor-
phisms on the metabolism of INH plays a role on
susceptibility to anti-TB-DIH [7]. But, we could not determine
genetic polymorphism because of the resource in this study.
Most of the time, anti-TB-DIH was expected to happen during
the initial phase (the first 2 months) of treatment, although it
may develop during the continuous phase. In the current
study, liver function test for monitoring of TB patients was
done only for the initial phase of treatment. We could not
get enough financial and time resources to follow the patients
during their continuation phase, and thus, we were unable to
describe the incidence during this phase.
Conclusions
Hepatotoxicity developed within the first 2 months after initi-
ating treatment. Patients taking anti-TB drugs should be fol-
lowed biochemically more frequently during the initial
phase of treatment than during the continuous phase.
Chronic high alcohol consumers had an increased risk of
developing anti-TB-DIH rates.Conflicts of interest
The authors declare that they have no competing interests.Acknowledgments
The authors would like to thank the data collectors for their
invaluable effort. Their deep gratitude also goes to the study
participants who were voluntary and took their time to give
all the relevant information for the study.R E F E R E N C E S[1] J.R. Mitchell, H.J. Zimmerman, K.G. Ishak, et al, Isoniazid liver
injury: clinical spectrum pathology and probable
pathogenesis, Ann. Intern. Med. 84 (1976) 181–192.
[2] H.A. Makhlouf, A. Helmy, E. Fawzy, et al, A prospective study
of antituberculous drug-induced hepatotoxicity in an area
endemic for liver diseases, Hepatol. Int. 2 (2008) 353–360.
[3] R. Shakya, B.S. Rao, B. Shrestha, Evaluation of risk factors for
antituberculosis drugs-induced hepatotoxicity in Nepalese
population, Kathmandu Univ. Med. J. 2 (2006) 2–4.
[4] N. Kaplowitz, Mechanisms of cell death and relevance to drug
hepatotoxicity, in: N. Kaplowitz, L. DeLeve (Eds.), Drug-
Induced Liver Disease, Marcel Dekker, New York, 2002, pp. 85–
95.
[5] J.J. Saukkonen, D.L. Cohn, R.M. Jasmer, et al, On the behalf of
ATS (American Thoracic Society): hepatotoxicity of
antituberculosis therapy, Am. J. Respir. Crit. Care Med. 174
(2006) 935–952.
[6] Federal Ministry of Health, Ethiopia. Guidelines for Clinical
and Programmatic Management of TB, TB/HIV and Leprosy in
Ethiopia, fifth edition, Addis Ababa, Ethiopia, 2013.
[7] D. Yee, C. Valiquette, M. Pelletier, et al, Antituberculous drug-
induced liver injury: current perspective, Trop. Gastroenterol.
1–10 (2008).
[8] S. Chitturi, G. Farrell, Drug-induced liver disease, in: E.R.
Schiff, M.F. Sorrell, W.C. Maddrey (Eds.), Schiff’s Diseases of
the Liver, ninth ed., Lippincott, Williams & Wilkins,
Philadelphia, 2002, pp. 1059–1128.
[9] D. Larrey, Epidemiology and individual susceptibility to
adverse drug reactions affecting the liver, Semin. Liver Dis. 22
(2002) 145–155.
[10] D.E. Snider, G.J. Caras, Isoniazid-associated hepatitis deaths:
a review of available information, Am. Rev. Respir. Dis. 145
(1992) 494–497.
[11] D.E. Kopanoff, D.E. Snider, G.J. Caras, Isoniazid-related
hepatitis, Am. Rev. Respir. Dis. 117 (1978) 991–1001.
[12] J.N. Pande, S.P. Singh, G.C. Khilnani, et al, Risk factors for
hepatotoxicity from antituberculosis drugs: a case-control
study, Thorax 51 (1996) 132–136.
[13] Y.S. Huang, H.D. Chern, W.J. Su, et al, Polymorphism of the N-
acetyltransferase 2 gene as a susceptibility risk factor for
antituberculosis drug-induced hepatitis, Hepatology 35 (2002)
883–889.
[14] S. Attri, S.V. Rana, K. Vaiphie, et al, Protective effect of N-
acetylcysteine in isoniazid induced hepatic injury in growing
rats, Indian J. Exp. Biol. 39 (2001) 436–440.
[15] H. Devarbhavi, R. Dierkhising, W.K. Kremers,
Antituberculosis therapy drug-induced liver injury and acute
liver failure, Hepatology 52 (2010) 798–799.
[16] J.Y. Wang, C.H. Liu, F.C. Hu, et al, Risk factors of hepatitis
during anti-tuberculous treatment and implications of
hepatitis virus load, J. Infect. 62 (2011) 448–455.
[17] R. Parthasarathy, G.R. Sarma, B. Janardhanam, et al, Hepatic
toxicity in South Indian patients during treatment of
tuberculosis with short-course regimens containing
20 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 5 ( 2 0 1 6 ) 1 4 –2 0isoniazid, rifampicin and pyrazinamide, Tubercle 67 (1986)
99–108.
[18] S.K. Sharma, A. Balamurugan, P.K. Saha, et al, Evaluation of
clinical and immunogenetic risk factors for the development
of hepatotoxicity during antituberculosis treatment, Am. J.
Respir. Crit. Care Med. 166 (2002) 916–919.
[19] M.A. Steele, R.F. Burk, R.M. DesPrez, Toxic hepatitis with
isoniazid and rifampin: a meta-analysis, Chest 99 (1991) 465–
471.
[20] J.J. Saukkonen, D.L. Cohn, R.M. Jasmer, et al, An official ATS
statement: hepatotoxicity of antituberculosis therapy, Am. J.
Respir. Crit. Care Med. 174 (2006) 935–952.
[21] K. Mahmood, A. Hussain, K.L. Jairamani, et al, Hepatotoxicity
with antituberculosis drugs: the risk factors, Pak. J. Med. Sci.
23 (2007) 33–38.
[22] C. Gronhagen-Riska, P.E. Hellstrom, B. Froseth, Predisposing
factors in hepatitis induced by isoniazid–rifampin treatment
of tuberculosis, Am. Rev. Respir. Dis. 118 (1978) 461–466.[23] M. Dossing, J.T. Wilcke, D.S. Askgaard, et al, Liver injury
during antituberculosis treatment: an 11-year study, Tuber.
Lung Dis. 77 (1996) 335–340.
[24] B.E. Senousy, S.I. Belal, P.V. Draganov, Hepatotoxic effects of
therapies for tuberculosis, Nat. Rev. Gastroenterol. Hepatol. 7
(2010) 543–556.
[25] A.C. Anand, A.K. Seth, M. Paul, et al, Risk factors of
hepatotoxicity during anti-tuberculosis treatment, Med. J.
Armed Forces India 62 (2006) 45–49.
[26] W. Marvin, Impacts of gender on drug responses, Drug Top.
(1998) 591–600.
[27] Y.S. Huang, H.D. Chern, W.J. Su, et al, Cytochrome P450 2E1
genotype and the susceptibility to antituberculosis drug-
induced hepatitis, Hepatology 37 (2003) 924–930.
[28] A. Fernandez-Villar, B. Sopena, J. Fernandez-Villar, et al, The
influence of risk factors on the severity of anti-tuberculosis
drug-induced hepatotoxicity, Int. J. Tuberc. Lung Dis. 8 (2004)
1499–1505.
